Finland

Finland

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
0.88 (0.75 - 1.03) 2019 Modelled IHME
0.88 (0.72 - 1.03) 2018 Modelled IHME
0.88 (0.70 - 1.05) 2017 Modelled IHME
0.89 (0.73 - 1.05) 2016 Modelled IHME
0.9 (0.73 - 1.07) 2015 Modelled IHME
0.9 (0.75 - 1.05) 2014 Modelled IHME
0.9 (0.75 - 1.04) 2013 Modelled IHME
0.9 (0.75 - 1.04) 2012 Modelled IHME
0.9 (0.75 - 1.05) 2011 Modelled IHME
0.9 (0.75 - 1.06) 2010 Modelled IHME
0.9 (0.76 - 1.05) 2009 Modelled IHME
0.91 (0.77 - 1.05) 2008 Modelled IHME
0.91 (0.78 - 1.06) 2007 Modelled IHME
0.92 (0.78 - 1.06) 2006 Modelled IHME
0.92 (0.78 - 1.07) 2005 Modelled IHME
0.93 (0.78 - 1.07) 2004 Modelled IHME
0.93 (0.78 - 1.08) 2003 Modelled IHME
0.94 (0.78 - 1.09) 2002 Modelled IHME
0.94 (0.78 - 1.10) 2001 Modelled IHME
0.95 (0.77 - 1.10) 2000 Modelled IHME
0.95 (0.78 - 1.11) 1999 Modelled IHME
0.95 (0.78 - 1.11) 1998 Modelled IHME
0.95 (0.78 - 1.12) 1997 Modelled IHME
0.95 (0.77 - 1.12) 1996 Modelled IHME
0.95 (0.77 - 1.12) 1995 Modelled IHME
0.95 (0.77 - 1.12) 1994 Modelled IHME
0.95 (0.78 - 1.13) 1993 Modelled IHME
0.95 (0.78 - 1.14) 1992 Modelled IHME
0.96 (0.78 - 1.14) 1991 Modelled IHME
0.96 (0.79 - 1.15) 1990 Modelled IHME
1.05 (0.10 - 10.75) 2015 Modelled WHO
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
0.38 (0.25 - 0.52) 2019 Modelled IHME
0.37 (0.23 - 0.52) 2018 Modelled IHME
0.36 (0.23 - 0.52) 2017 Modelled IHME
0.38 (0.24 - 0.52) 2016 Modelled IHME
0.39 (0.25 - 0.54) 2015 Modelled IHME
0.39 (0.25 - 0.53) 2014 Modelled IHME
0.39 (0.24 - 0.53) 2013 Modelled IHME
0.39 (0.24 - 0.54) 2012 Modelled IHME
0.38 (0.23 - 0.54) 2011 Modelled IHME
0.38 (0.23 - 0.55) 2010 Modelled IHME
0.38 (0.24 - 0.56) 2009 Modelled IHME
0.39 (0.24 - 0.57) 2008 Modelled IHME
0.39 (0.24 - 0.58) 2007 Modelled IHME
0.39 (0.25 - 0.58) 2006 Modelled IHME
0.39 (0.25 - 0.59) 2005 Modelled IHME
0.39 (0.26 - 0.58) 2004 Modelled IHME
0.4 (0.26 - 0.56) 2003 Modelled IHME
0.4 (0.27 - 0.55) 2002 Modelled IHME
0.41 (0.27 - 0.54) 2001 Modelled IHME
0.41 (0.27 - 0.55) 2000 Modelled IHME
0.41 (0.27 - 0.55) 1999 Modelled IHME
0.41 (0.27 - 0.56) 1998 Modelled IHME
0.41 (0.26 - 0.57) 1997 Modelled IHME
0.42 (0.26 - 0.58) 1996 Modelled IHME
0.42 (0.26 - 0.59) 1995 Modelled IHME
0.41 (0.26 - 0.58) 1994 Modelled IHME
0.41 (0.27 - 0.58) 1993 Modelled IHME
0.41 (0.27 - 0.58) 1992 Modelled IHME
0.41 (0.28 - 0.57) 1991 Modelled IHME
0.4 (0.28 - 0.56) 1990 Modelled IHME
1.05 (0.11 - 10.74) 2015 Modelled WHO
Showing out of
Show more
Prisoners
Download
Value (%) Year Type Source
0.5 (0.10 - 1.90) 2006 Survey/reported Viitanen P et al, 2011

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
11 (7 - 17) 2019 Modelled IHME
11 (7 - 17) 2018 Modelled IHME
11 (7 - 17) 2017 Modelled IHME
11 (7 - 17) 2016 Modelled IHME
11 (7 - 17) 2015 Modelled IHME
11 (8 - 17) 2014 Modelled IHME
11 (8 - 17) 2013 Modelled IHME
11 (8 - 16) 2012 Modelled IHME
11 (8 - 17) 2011 Modelled IHME
12 (8 - 17) 2010 Modelled IHME
12 (8 - 17) 2009 Modelled IHME
12 (8 - 17) 2008 Modelled IHME
12 (8 - 17) 2007 Modelled IHME
12 (8 - 17) 2006 Modelled IHME
12 (8 - 17) 2005 Modelled IHME
12 (8 - 17) 2004 Modelled IHME
12 (8 - 17) 2003 Modelled IHME
12 (8 - 17) 2002 Modelled IHME
12 (8 - 17) 2001 Modelled IHME
12 (8 - 18) 2000 Modelled IHME
12 (8 - 18) 1999 Modelled IHME
12 (8 - 18) 1998 Modelled IHME
12 (9 - 18) 1997 Modelled IHME
13 (9 - 18) 1996 Modelled IHME
13 (9 - 18) 1995 Modelled IHME
13 (9 - 19) 1994 Modelled IHME
13 (9 - 18) 1993 Modelled IHME
13 (9 - 19) 1992 Modelled IHME
13 (9 - 19) 1991 Modelled IHME
13 (9 - 19) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
373 2017 Survey/reported EMCDDA, 2019
312 (214 - 350) 2015 Survey/reported EMCDDA, 2017
Showing out of
Show more
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
No
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
HCV testing policy
Risk-based
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
Yes
% of substance use disorder facilities offering hepatitis testing
Most (61-100%)
% of substance use disorder facilities offering hepatitis treatment
None

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
0.95 (0.77 - 1.16) 2019 Modelled IHME
0.94 (0.78 - 1.14) 2018 Modelled IHME
0.94 (0.78 - 1.14) 2017 Modelled IHME
0.93 (0.76 - 1.13) 2016 Modelled IHME
0.93 (0.76 - 1.13) 2015 Modelled IHME
0.93 (0.76 - 1.13) 2014 Modelled IHME
0.93 (0.76 - 1.13) 2013 Modelled IHME
0.92 (0.76 - 1.12) 2012 Modelled IHME
0.92 (0.76 - 1.12) 2011 Modelled IHME
0.92 (0.76 - 1.12) 2010 Modelled IHME
0.92 (0.75 - 1.11) 2009 Modelled IHME
0.91 (0.74 - 1.09) 2008 Modelled IHME
0.89 (0.73 - 1.08) 2007 Modelled IHME
0.88 (0.72 - 1.07) 2006 Modelled IHME
0.86 (0.71 - 1.06) 2005 Modelled IHME
0.85 (0.70 - 1.04) 2004 Modelled IHME
0.84 (0.69 - 1.02) 2003 Modelled IHME
0.82 (0.68 - 1) 2002 Modelled IHME
0.81 (0.66 - 0.98) 2001 Modelled IHME
0.8 (0.65 - 0.97) 2000 Modelled IHME
0.79 (0.64 - 0.96) 1999 Modelled IHME
0.78 (0.64 - 0.95) 1998 Modelled IHME
0.77 (0.63 - 0.94) 1997 Modelled IHME
0.76 (0.63 - 0.93) 1996 Modelled IHME
0.76 (0.62 - 0.93) 1995 Modelled IHME
0.75 (0.61 - 0.92) 1994 Modelled IHME
0.75 (0.61 - 0.92) 1993 Modelled IHME
0.74 (0.61 - 0.91) 1992 Modelled IHME
0.74 (0.60 - 0.91) 1991 Modelled IHME
0.74 (0.60 - 0.91) 1990 Modelled IHME
Showing out of
Show more

Prevalence of anti-HCV

National
Download
Value (%) Year Type Source
0.7 (0.60 - 0.90) 2014 Modelled Gower et al, 2014
People who inject drugs (PWID)
Download
Value (%) Year Type Source
73.7 (69.90 - 77.20) 2014 Survey/reported EMCDDA, 2016
60.5 (56.80 - 64.30) 2009 Survey/reported EMCDDA
Showing out of
Show more
Prisoners
Download
Value (%) Year Type Source
45.8 (40.80 - 51) 2006 Survey/reported Viitanen P et al, 2011

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
40 (30 - 50) 2019 Modelled IHME
40 (30 - 50) 2018 Modelled IHME
40 (30 - 50) 2017 Modelled IHME
40 (30 - 50) 2016 Modelled IHME
40 (30 - 50) 2015 Modelled IHME
40 (30 - 50) 2014 Modelled IHME
39 (30 - 50) 2013 Modelled IHME
39 (30 - 49) 2012 Modelled IHME
39 (30 - 49) 2011 Modelled IHME
39 (29 - 49) 2010 Modelled IHME
39 (29 - 49) 2009 Modelled IHME
39 (29 - 49) 2008 Modelled IHME
39 (30 - 49) 2007 Modelled IHME
39 (30 - 49) 2006 Modelled IHME
39 (30 - 49) 2005 Modelled IHME
39 (30 - 50) 2004 Modelled IHME
40 (30 - 50) 2003 Modelled IHME
40 (30 - 50) 2002 Modelled IHME
40 (31 - 50) 2001 Modelled IHME
41 (31 - 51) 2000 Modelled IHME
41 (31 - 50) 1999 Modelled IHME
40 (30 - 50) 1998 Modelled IHME
41 (31 - 50) 1997 Modelled IHME
40 (30 - 50) 1996 Modelled IHME
40 (30 - 50) 1995 Modelled IHME
40 (30 - 50) 1994 Modelled IHME
40 (30 - 49) 1993 Modelled IHME
39 (30 - 49) 1992 Modelled IHME
39 (29 - 49) 1991 Modelled IHME
39 (29 - 49) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
300 2017 Survey/reported EMCDDA, 2019
312 (214 - 350) 2015 Survey/reported EMCDDA, 2017
Showing out of
Show more
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
No
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
HCV testing policy
Risk-based
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
Yes
% of substance use disorder facilities offering hepatitis testing
Most (61-100%)
% of substance use disorder facilities offering hepatitis treatment
None

Overview

HBV elimination goal
HCV elimination goal

Prevalence (national)

Modelled

HBV (HBsAg+)
0.88 (%)
2019
(0.75 - 1.03(%))
IHME
HCV (RNA/cAg+)
0.95 (%)
2019
(0.77 - 1.16(%))
IHME

Survey/surveillance

No data available
No data available

Hepatitis related deaths (national)

Modelled

HBV
190
2019
(143 - 251)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
389
2019
(306 - 486)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
0.38 (%)
2019, latest modelled
(0.25 - 0.52(%))
IHME

Prevalence PWID

HCV
73.70 (%)
2014, survey/surveillance
(69.90 - 77.20(%))
EMCDDA, 2016

Birth dose vaccination coverage (national)

Survey/surveillance

No data available

No. of syringes/PWID/year

Survey/surveillance

HCV
373
2017
EMCDDA, 2019
Eligible for HBV generic medicines
Eligible for HCV generic medicines